Roivant Cuts Multiple R&D Programs As It Takes On Pfizer’s TYK2/JAK1 Inhibitor
Sickle Cell, Dermatology And Cancer Drugs Among Discontinued Assets
Roivant swapped out multiple programs to conserve cash and bring in a late-stage Pfizer asset • Source: Shutterstock 
